Invasive aspergillosis in transplant recipients

Paterson, David L. and Singh, Nina (1999) Invasive aspergillosis in transplant recipients. Medicine, 78 2: 123-138. doi:10.1097/00005792-199903000-00003

Author Paterson, David L.
Singh, Nina
Title Invasive aspergillosis in transplant recipients
Journal name Medicine   Check publisher's open access policy
ISSN 0025-7974
Publication date 1999-03
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1097/00005792-199903000-00003
Open Access Status DOI
Volume 78
Issue 2
Start page 123
End page 138
Total pages 16
Place of publication Baltimore, Md., U. S. A.
Publisher Lippincott Williams & Wilkins
Language eng
Subject 1103 Clinical Sciences
Abstract Infections and rejection have long been the leading causes of morbidity and mortality in transplant recipients. Although recent advances in immunosuppression, prophylaxis, and treatment of infections such as cytomegalovirus have resulted in improved outcome in transplant recipients, invasive aspergillosis remains a scourge of transplantation medicine. Invasive aspergillosis has a mortality in this patient population of up to 90% and accounts for 10%-15% of all deaths of transplant recipients in the first year after transplant. Of more than 20,000 transplant recipients who have been reported, incidence of invasive aspergillosis has ranged from 0.7% in kidney transplant recipients to 8.4% in lung transplant recipients. Definite risk factors for development of invasive aspergillosis exist, including delayed engraftment and severe graft-versus-host disease in bone marrow transplant recipients and poor graft function, cytomegalovirus infection, and renal failure in solid-organ transplant recipients. Although a number of prophylactic regimens are in widespread use, none has been shown conclusively to reduce the incidence of invasive aspergillosis. Reducing environmental exposure to Aspergillus, early diagnosis of the infection by means of antigen detection in serum, and use of high-resolution computed tomography are alternatives to use of prophylaxis but have not been systematically evaluated. New treatment options include early surgical intervention in cases of localized disease; lipid preparations of amphotericin, itraconazole, or voriconazole; and immunotherapy with G-CSF or GM-CSF and interferon-gamma.
Keyword Bone-marrow Transplantation
Liposomal Amphotericin-B
Colony-stimulating Factor
Latex Agglutination-test
Orthotopic Liver-transplantation
Single-lung Transplantation
Selective Bowel Decontamination
Primary Cutaneous Aspergillosis
Multiple-dose Pharmacokinetics
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: UQ Centre for Clinical Research Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 223 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 291 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 07 Sep 2010, 17:08:55 EST